奥美拉唑钠
中文名称 | 奥美拉唑钠 |
---|---|
中文同义词 | 5-甲氧基-2-[(4-甲氧基-3,5-二甲基-2-吡啶基)-甲基亚砜]-3H-苯并咪唑钠盐;奥美拉唑钠盐;奥美拉唑钠水合物;奥美拉唑钠OMEPRAZOLE SODIUM;6-甲氧基-2-(((4-甲氧基-3,5-二甲基吡啶-2-基)甲基)亚磺酰基)苯并[D]咪唑钠盐;奥美拉唑钠一水合物;优选]OMEPRAZOLE SODIUM;6-甲氧基-2-[[(4-甲氧基-3,5-二甲基-2-吡啶基]亚磺酰基]苯并咪唑-1-钠盐 |
英文名称 | Omeprazole sodium |
英文同义词 | sodium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]benzoimidazole;OMEPRAZOLE SODIUM;5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole sodium salt;Omeprazole powder/pellets/sodium;Omeprazole, sodium salt;odiuM 5-Methoxy-2-[(4-Methoxy-3,5-diMethyl-pyridin-2-yl)Methylsulfinyl]benzoiMidazole;1H-BenziMidazole, 6-Methoxy-2-[[(4-Methoxy-3,5-diMethyl-2-pyridinyl)Methyl]sulfinyl]-, sodiuM salt (1:1);omeprazole sodium:sodium 5-methoxy-2-((4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl)benzoIMIDAZOLE |
CAS号 | 95510-70-6 |
分子式 | C17H20N3NaO3S |
分子量 | 369.41 |
EINECS号 | 623-285-9 |
相关类别 | 医药原料药;化合物;中药对照品;医用原料;原料中间体-原料药;中间体;医药原料;兽药原料药;Active Pharmaceutical Ingredients;Omeprazole;Digestive System;消化系统;原料药;兽药原料;医用原料;医药原料;标准品;原料药;化学原料;无机盐;化学试剂;原料;试剂 |
Mol文件 | 95510-70-6.mol |
结构式 |
奥美拉唑钠 性质
熔点 | >165°C (dec.) |
---|---|
储存条件 | under inert gas (nitrogen or Argon) at 2-8°C |
溶解度 | 易溶于水和乙醇(96%),溶于丙二醇,极微溶于二氯甲烷。 |
形态 | 固体 |
颜色 | 白色至类白色 |
稳定性 | 吸湿性 |
CAS 数据库 | 95510-70-6(CAS DataBase Reference) |
Target | Value |
CYP2C19
() | |
Proton pump
() |
Omeprazole (H 16868) is a proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome. Omeprazole (H 16868) virtually eliminated intragastric acidity in all patients: the median 24 hour intragastric pH rose from 1.4 to 5.3 and the mean hourly hydrogen ion activity fell from 38.50 to 1.95 mmol(mEq)/1 (p less than 0.001). This inhibition of 24 hour intragastric acidity is more profound than that previously reported with either cimetidine 1 g daily or ranitidine 300 mg daily. The pharmacokinetics of omeprazole were studied in a group of healthy male subjects after single and repeated oral doses of 30 and 60 mg. Absorption of Omeprazole (H 16868) from its enteric-coated formulation was unpredictable. There was a highly significant increase in the area under the plasma concentration time curve (AUC) after repeated dosing. Omeprazole (H 16868) increases its own relative availability following repeated dosing. This may be due to inhibition of gastric acid secretion by omeprazole which is an acid-labile compound.
Omeprazole sodium is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-B0113A | 奥美拉唑钠 Omeprazole sodium | 95510-70-6 | 100mg | 100元 |
2024/08/19 | HY-B0113A | 奥美拉唑钠 Omeprazole sodium | 95510-70-6 | 10mM * 1mLin DMSO | 110元 |